Roche signs on for rights to Plexxikon's PLX4032 cancer agent
Plexxikon (uses Scaffold-Based Drug Discovery technology for structural screening and analysis of small molecules) has licensed Roche exclusive worldwide development and marketing rights to PLX4032 for cancer.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.